Contents

Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD)

June 1, 2019

Clinical trial

Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial.

Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, McGuinness MB, Fletcher EL, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Lek JJ, Harper CA, Wickremasinghe SS, Sandhu SS, Baglin EK, Sharangan P, Braat S, Luu CD.

Ophthalmology. 2019 Jun;126(6):829-838.
Full text | Metrics.

Main finding: In patient with intermediate AMD, subthreshold nanosecond laser (SNL) did not significantly slow progression rate to late AMD. A post hoc analysis however showed SNL may slow progression in patients without coexistent reticular pseudodrusen, and may be inappropriate in patients with the latter.

 

  • Purpose: To evaluate the safety of SNL treatment in intermediate AMD and its efficacy for slowing progression to late AMD.
  • Study type: Randomized clinical trial
  • Condition: AMD (intermediate severity)

Participants: ≥50yo with intermediate AMD (at least 1 druse more than 125 μm in diameter), BCVA 20/40 or better

 

  • n=292

 

Intervention:

 

Group 1: Subthreshold nanosecond laser (Retinal Rejuvenation Therapy)
Group 2: Sham

Progression to late AMD was not slowed significantly with SNL treatment compared with sham.

 

A post hoc analysis however showed progression was slowed in participants without coexistent reticular pseudodrusen at baseline, and an increased progression rate in participants with reticular pseudodrusen.

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed